December 23, 2020

Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #COVID19–Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the United Kingdom and South Africa. This new variant strain of SARS-CoV-2 contains multiple spike protein mutations as well as mutations in other areas of the viral genom


Leave Comment


Your Name *
Your Email *
Your Website
Comment *